NCT07181499招募中2 期
A Study Evaluating the Efficacy and Safety of Pemetrexed Combined With Platinum-Based Chemotherapy Followed by Befotertinib in Patients With Non-Small Cell Lung Cancer After Third-Generation EGFR TKI Resistance
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- progression free survival
研究概览
简要总结
Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations. Third-generation EGFR-TKIs achieve a median PFS of about 20 months as first-line therapy, but resistance eventually develops. Studies like MARIPOSA-2 confirm that amivantamab combined with chemotherapy ± lazertinib or immunotherapy regimens (ivucitinib/sintilimab + bevacizumab + chemotherapy) can extend median PFS post-resistance from approximately 4 months to 6-8 months. As a third-generation TKI, befitinib has demonstrated PFS of 16-22 months in both first-line and post-T790M mutation settings. This study aims to further evaluate the feasibility and safety of "pemetrexed + carboplatin followed by befotertinib" for patients resistant to third-generation TKIs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years;
- •Histologically or cytologically confirmed advanced or metastatic non-squamous NSCLC; and prior resistance to third-generation EGFR TKIs, with EGFR-sensitive mutations confirmed via tissue or blood samples (defined as: 19 Del or 21 L858R);
- •Exclusion of small cell lung cancer (SCLC) or squamous cell carcinoma (SqCC) transformation, and known NSCLC with clear targetable mutations for targeted therapy, such as HER2, MET amplification (GCN ≥ 5), KRAS G12C mutation, BRAF V600E mutation, RET fusion mutation, ALK fusion mutation, NTRK fusion mutation, etc.;
- •ECOG performance status (PS) score of 0-2;
- •Life expectancy of at least 12 weeks;
- •Ability to swallow oral medications;
- •Adequate organ system function, defined as follows and determined based on investigator judgment:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
- •Platelets ≥ 100 x 10⁹/L;
- •Hemoglobin ≥ 9 g/dL (≥ 90 g/L). Note: Blood transfusions are permitted to achieve the required hemoglobin level;
- •Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);
- •If no liver metastases: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; if liver metastases present: ≤ 5 × ULN;
- •Creatinine ≤1.5 × ULN. If ≥1.5 × ULN, patients remain eligible if the Cockcroft-Gault-calculated creatinine clearance ≥50 mL/min (0.83 mL/s);
- •Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to study drug initiation and agree to use a medically approved highly effective contraceptive method (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 3 months after the last study drug administration; Male subjects with female partners of childbearing potential must be surgically sterilized or agree to use an effective method of contraception during the study period and for 3 months after the last study dose.
- •Voluntarily agree and be capable of adhering to the trial and follow-up procedures.
- •Be able to understand the nature of the trial and complete the written informed consent form.
排除标准
- •Rare EGFR mutations;
- •Prior treatment with pemetrexed and platinum-based chemotherapy regimens;
- •Advanced and/or symptomatic brain metastases (measurable or non-measurable) and/or leptomeningeal metastases;
- •Active hepatitis B (serum HBV DNA ≥10⁴ copies/mL [i.e., 20,000 IU/mL]), hepatitis C virus antibody positive, HIV antibody positive, or treponema pallidum antibody positive;
- •Women of childbearing potential with a positive serum pregnancy test within 7 days prior to treatment initiation, pregnant or lactating women, or male and female subjects not using effective contraception or planning pregnancy during treatment and for 3 months post-treatment;
- •Patients who used or require concomitant use of the following drugs within 14 days prior to the first dose or during treatment: drugs associated with QTc prolongation and/or risk of torsades de pointes ventricular tachycardia; strong CYP3A inhibitors or inducers;
- •Patients who underwent major surgery or immunotherapy within 4 weeks prior to the first dose; patients who received radiotherapy within 2 weeks prior to the first dose.
- •Imaging (CT or MRI) demonstrating tumor invasion of major vessels, or a high likelihood of tumor invasion into critical vessels causing fatal hemorrhage during the study period;
- •History of interstitial lung disease, drug-induced interstitial disease, or any clinically evident active interstitial lung disease; presence of idiopathic pulmonary fibrosis identified on baseline CT scan;
- •Other severe acute or chronic medical conditions, including uncontrolled diabetes, medical or psychiatric disorders, or laboratory abnormalities, that in the investigator's judgment may increase study-related risks or interfere with interpretation of study results;
- •Other conditions deemed by the investigator to be unsuitable for participation in this trial.
研究组 & 干预措施
Group 1
Experimental
pemetrexed (500 mg/m2) and carboplatin (AUC 5), administered every 3 weeks. After 2 to 4 cycles, received Befotertinib (75-100 mg)
干预措施: Befotertinib (Drug)
Group 1
Experimental
pemetrexed (500 mg/m2) and carboplatin (AUC 5), administered every 3 weeks. After 2 to 4 cycles, received Befotertinib (75-100 mg)
干预措施: Pemetrexed + Carboplatin (Drug)
结局指标
主要结局
progression free survival
时间窗: From enrollment to the end of treatment at 12 months
It refers to the time from the start of treatment until the tumor progresses or until death occurs for any reason (whichever occurs first).
次要结局
- objective remission rate(From enrollment to the end of treatment at 12 month)
- Disease control rate(From enrollment to the end of treatment at 12 months)
- overall survival(From enrollment to the end of treatment at 36 months)
- adverse event(From enrollment to the end of treatment at 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
3 期
Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction ChemotherapyCarcinoma, Non-small-cell LungNCT02004184Norwegian University of Science and Technology230
撤回
2 期
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT01533727Sun Yat-sen University
已完成
不适用
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of ChemotherapyNon Small Cell Lung CancerENT CancerBladder CancerNCT04487457University Hospital, Tours31
已完成
不适用
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung CancerNon Small Cell Lung CancerNCT06068842AbbVie579
招募中
2 期
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT06236438AbbVie840